JP2022521792A5 - - Google Patents

Info

Publication number
JP2022521792A5
JP2022521792A5 JP2021550014A JP2021550014A JP2022521792A5 JP 2022521792 A5 JP2022521792 A5 JP 2022521792A5 JP 2021550014 A JP2021550014 A JP 2021550014A JP 2021550014 A JP2021550014 A JP 2021550014A JP 2022521792 A5 JP2022521792 A5 JP 2022521792A5
Authority
JP
Japan
Prior art keywords
cancer
dna
cell
cancer vaccine
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021550014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521792A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020224 external-priority patent/WO2020176797A1/en
Publication of JP2022521792A publication Critical patent/JP2022521792A/ja
Publication of JP2022521792A5 publication Critical patent/JP2022521792A5/ja
Pending legal-status Critical Current

Links

JP2021550014A 2019-02-27 2020-02-27 癌を治療するための免疫療法的併用 Pending JP2022521792A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962811459P 2019-02-27 2019-02-27
US62/811,459 2019-02-27
US201962825487P 2019-03-28 2019-03-28
US62/825,487 2019-03-28
US201962838180P 2019-04-24 2019-04-24
US62/838,180 2019-04-24
US201962881832P 2019-08-01 2019-08-01
US62/881,832 2019-08-01
PCT/US2020/020224 WO2020176797A1 (en) 2019-02-27 2020-02-27 Immunotherapeutic combination for treating cancer

Publications (2)

Publication Number Publication Date
JP2022521792A JP2022521792A (ja) 2022-04-12
JP2022521792A5 true JP2022521792A5 (cg-RX-API-DMAC7.html) 2023-03-06

Family

ID=72238533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550014A Pending JP2022521792A (ja) 2019-02-27 2020-02-27 癌を治療するための免疫療法的併用

Country Status (4)

Country Link
EP (1) EP3930747A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022521792A (cg-RX-API-DMAC7.html)
CN (1) CN113631185A (cg-RX-API-DMAC7.html)
WO (1) WO2020176797A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165952A1 (en) 2020-05-01 2023-06-01 Nykode Therapeutics ASA Betacoronavirus prophylaxis and therapy
AU2022244191A1 (en) * 2021-03-26 2023-09-28 Nykode Therapeutics ASA Therapeutic combination for treating cancer
KR20240004403A (ko) * 2021-03-29 2024-01-11 오디 쎄라퓨틱스 리미티드 단백질-거대분자 접합체 및 이의 사용 방법
WO2022233851A1 (en) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
EP4337247A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
IL308310A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Co-expression of immune-stimulating structures and compounds
WO2022238432A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
KR20240007235A (ko) 2021-05-10 2024-01-16 니코데 테라퓨틱스 에이에스에이 관용-유도 컨스트럭트 및 조성물 및 면역 장애의 치료를 위한 그들의 용도
EP4426344A1 (en) 2021-11-03 2024-09-11 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
US20260193669A1 (en) 2022-11-09 2026-07-09 Nykode Therapeutics ASA Co-Expression of Constructs and Polypeptides
CN116217676B (zh) * 2023-01-30 2025-07-29 广州呈源生物免疫技术有限公司 人乳头瘤病毒抗原肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025647A1 (en) * 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
TW201708536A (zh) * 2015-05-26 2017-03-01 艾法西斯公司 個人化的基於遞送載體之免疫療法及其用途
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
AU2017315468B2 (en) * 2016-08-25 2020-02-13 Nantomics, Llc Immunotherapy markers and uses therefor
CA3043597A1 (en) * 2016-11-10 2018-05-17 Nektar Therapeutics Immunotherapeutic tumor treatment method
KR20240113607A (ko) * 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신

Similar Documents

Publication Publication Date Title
Marin-Acevedo et al. Cancer immunotherapy beyond immune checkpoint inhibitors
Pollack et al. Emerging targeted and immune-based therapies in sarcoma
Kiesgen et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
KR102470294B1 (ko) 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합
Dammeijer et al. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
Coukos et al. Opportunities in immunotherapy of ovarian cancer
Goel et al. Cancer immunotherapy in clinical practice—the past, present, and future
MX2021011500A (es) Anticuerpos multiespecificos egfr x cd28.
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
JP2017531687A5 (cg-RX-API-DMAC7.html)
Martin et al. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
RU2014111999A (ru) Антитела к C10RF32 и их применения для лечения рака
Houot et al. Vaccines for lymphomas: idiotype vaccines and beyond
JP2017523784A5 (cg-RX-API-DMAC7.html)
JP2022532490A5 (cg-RX-API-DMAC7.html)
RU2016147206A (ru) Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
Berinstein Enhancing cancer vaccines with immunomodulators
RU2013155455A (ru) Антитела для лечения раковых заболеваний, при которых эскспрессируется клаудин 6
RU2011115117A (ru) Нацеленные средства связывания, направленные на dll4, и их применение
JP2014502955A5 (cg-RX-API-DMAC7.html)
CN113543809A (zh) 用于治疗癌症的免疫疗法
IL300629A (en) Preparations and methods for the treatment of EGFR positive cancer
JP2022512944A5 (cg-RX-API-DMAC7.html)
Ströhlein et al. The current status of immunotherapy in peritoneal carcinomatosis
JP2022512384A5 (cg-RX-API-DMAC7.html)